RxDoctor Payments Data

Rahul Sharma, MD

Interventional Cardiology · Stanford, CANPI 1548735509

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Edwards Lifesciences at 49.9% of the total. Reporting peaked in 2023 at $324,972 and has fallen 57.4% since, to $138,515 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,033,088in general payments, 2019–2025

Across 1,800 payments — averaging $573.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$516K
  • Cathworks, Inc.$257K
  • Abbott$103K
  • Siemens Medical Solutions USA, Inc.$44K
  • Shockwave Medical, Inc$40K
  • Medtronic$20K
  • plus $53K from 21 others
$5,556,624in research payments, 2019–2025

Across 251 payments — averaging $22,138 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$4.8M
  • Boston Scientific$537K
  • Abbott$177K
  • Biosense Webster, Inc.$21K
  • Medtronic$5K

What the payments were for

  • Consulting fees$604,57459%
  • Speaking & faculty fees$164,48316%
  • Travel & lodging$187,31218%
  • Food & beverage$76,5697%
  • Education$10%
  • Entertainment$1500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,033,088 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$281,047
Medicare patients
428
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate22$392
Prednisone17$56

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →